Black Diamond Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Black Diamond Therapeutics

12/03/2024 13:31

* Black Diamond Therapeutics Inc  BDTX.OQ  reported a
quarterly
adjusted loss of 34 cents​​ per share for the quarter ended in
December, higher than the same quarter last year, when the
company reported EPS of -59 cents.  The mean expectation of
six analysts for the quarter was for a loss of 47 cents per
share. Wall Street expected results to range from -50 cents
to -44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 34 cents​.
    * The company reported a quarterly loss of $19.41 million.
    * Black Diamond Therapeutics Inc shares had risen by 42.3%
this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Black Diamond
Therapeutics Inc is $10.00 
This summary was machine generated from LSEG data March 12 at
01:30 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.47          -0.34          Beat
 Sep. 30 2023      -0.49          -0.45          Beat
 Jun. 30 2023      -0.54          -0.52          Beat
 Mar. 31 2023      -0.61          -0.57          Beat